PubMed: Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome

PubMed: Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome

NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. Epub 2023 Jun 7.

ABSTRACT

Tetrahydrocannabinol and Cannabidiol in Tourette SyndromeThis randomized controlled crossover trial examined the use of oral tetrahydrocannabinol (THC) with cannabidiol (CBD) to reduce tics in patients with severe Tourette syndrome. Treatment with THC and CBD for 6 weeks led to a significant reduction in tics as measured by the total tic score on the Yale Global Tic Severity Scale, without major adverse effects.

PMID:38320199 | DOI:10.1056/EVIDoa2300012

https://pubmed.ncbi.nlm.nih.gov/38320199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Ds1JEbG0OWaBdqM3tTUGjkFhFGaOtMecPdpuvzbuubWi6d9Fn&fc=20231022105433&ff=20240206192233&v=2.18.0 February 6, 2024 11:00 am